vs
F5, Inc.（FFIV）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
F5, Inc.的季度营收约是Royalty Pharma plc的1.3倍（$811.7M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 18.2%，领先16.2%），F5, Inc.同比增速更快（11.0% vs 4.8%），过去两年F5, Inc.的营收复合增速更高（8.0% vs 4.6%）
F5, Inc.是一家美国科技企业，专注于应用安全、多云管理、线上反欺诈、应用交付网络（ADN）相关业务，同时提供应用可用性与性能优化、网络安全、访问授权管理等产品及解决方案，助力各行业客户保障数字化业务稳定运营，提升运行效率。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
FFIV vs RPRX — 直观对比
营收规模更大
FFIV
是对方的1.3倍
$622.0M
营收增速更快
FFIV
高出6.2%
4.8%
净利率更高
RPRX
高出16.2%
18.2%
两年增速更快
FFIV
近两年复合增速
4.6%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $811.7M | $622.0M |
| 净利润 | $148.0M | $214.2M |
| 毛利率 | 81.4% | — |
| 营业利润率 | 22.1% | 62.4% |
| 净利率 | 18.2% | 34.4% |
| 营收同比 | 11.0% | 4.8% |
| 净利润同比 | 1.5% | 2.9% |
| 每股收益（稀释后） | $2.58 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FFIVRPRX
| Q1 26 | $811.7M | — | ||
| Q4 25 | $822.5M | $622.0M | ||
| Q3 25 | $810.1M | $609.3M | ||
| Q2 25 | $780.4M | $578.7M | ||
| Q1 25 | $731.1M | $568.2M | ||
| Q4 24 | $766.5M | $593.6M | ||
| Q3 24 | $746.7M | $564.7M | ||
| Q2 24 | $695.5M | $537.3M |
净利润FFIVRPRX
| Q1 26 | $148.0M | — | ||
| Q4 25 | $180.1M | $214.2M | ||
| Q3 25 | $190.5M | $288.2M | ||
| Q2 25 | $189.9M | $30.2M | ||
| Q1 25 | $145.5M | $238.3M | ||
| Q4 24 | $166.4M | $208.2M | ||
| Q3 24 | $165.3M | $544.0M | ||
| Q2 24 | $144.1M | $102.0M |
毛利率FFIVRPRX
| Q1 26 | 81.4% | — | ||
| Q4 25 | 81.5% | — | ||
| Q3 25 | 82.2% | — | ||
| Q2 25 | 81.0% | — | ||
| Q1 25 | 80.7% | — | ||
| Q4 24 | 81.7% | — | ||
| Q3 24 | 80.8% | — | ||
| Q2 24 | 80.4% | — |
营业利润率FFIVRPRX
| Q1 26 | 22.1% | — | ||
| Q4 25 | 26.0% | 62.4% | ||
| Q3 25 | 25.4% | 70.1% | ||
| Q2 25 | 25.2% | 36.3% | ||
| Q1 25 | 21.7% | 94.0% | ||
| Q4 24 | 26.8% | 60.9% | ||
| Q3 24 | 25.6% | — | ||
| Q2 24 | 23.4% | 50.2% |
净利率FFIVRPRX
| Q1 26 | 18.2% | — | ||
| Q4 25 | 21.9% | 34.4% | ||
| Q3 25 | 23.5% | 47.3% | ||
| Q2 25 | 24.3% | 5.2% | ||
| Q1 25 | 19.9% | 41.9% | ||
| Q4 24 | 21.7% | 35.1% | ||
| Q3 24 | 22.1% | 96.3% | ||
| Q2 24 | 20.7% | 19.0% |
每股收益（稀释后）FFIVRPRX
| Q1 26 | $2.58 | — | ||
| Q4 25 | $3.10 | $0.49 | ||
| Q3 25 | $3.25 | $0.67 | ||
| Q2 25 | $3.25 | $0.07 | ||
| Q1 25 | $2.48 | $0.55 | ||
| Q4 24 | $2.82 | $0.46 | ||
| Q3 24 | $2.79 | $1.21 | ||
| Q2 24 | $2.44 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $3.6B | $9.7B |
| 总资产 | $6.5B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资FFIVRPRX
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.2B | $618.7M | ||
| Q3 25 | $1.3B | $938.9M | ||
| Q2 25 | $1.4B | $631.9M | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.2B | $929.0M | ||
| Q3 24 | $1.1B | $950.1M | ||
| Q2 24 | $935.6M | $1.8B |
总债务FFIVRPRX
| Q1 26 | — | — | ||
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
股东权益FFIVRPRX
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.5B | $9.7B | ||
| Q3 25 | $3.6B | $9.6B | ||
| Q2 25 | $3.5B | $9.5B | ||
| Q1 25 | $3.3B | $9.8B | ||
| Q4 24 | $3.2B | $10.3B | ||
| Q3 24 | $3.1B | $10.3B | ||
| Q2 24 | $3.0B | $9.8B |
总资产FFIVRPRX
| Q1 26 | $6.5B | — | ||
| Q4 25 | $6.3B | $19.6B | ||
| Q3 25 | $6.3B | $19.3B | ||
| Q2 25 | $6.1B | $18.3B | ||
| Q1 25 | $5.9B | $17.6B | ||
| Q4 24 | $5.9B | $18.2B | ||
| Q3 24 | $5.6B | $18.0B | ||
| Q2 24 | $5.4B | $17.7B |
负债/权益比FFIVRPRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $525.1M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 3.55× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FFIVRPRX
| Q1 26 | $525.1M | — | ||
| Q4 25 | $159.2M | $827.1M | ||
| Q3 25 | $208.1M | $702.6M | ||
| Q2 25 | $282.2M | $364.0M | ||
| Q1 25 | $256.6M | $596.1M | ||
| Q4 24 | $202.8M | $742.5M | ||
| Q3 24 | $246.5M | $703.6M | ||
| Q2 24 | $159.0M | $658.2M |
自由现金流FFIVRPRX
| Q1 26 | — | — | ||
| Q4 25 | $149.5M | — | ||
| Q3 25 | $191.9M | — | ||
| Q2 25 | $273.7M | — | ||
| Q1 25 | $246.1M | — | ||
| Q4 24 | $194.7M | — | ||
| Q3 24 | $240.4M | — | ||
| Q2 24 | $153.1M | — |
自由现金流率FFIVRPRX
| Q1 26 | — | — | ||
| Q4 25 | 18.2% | — | ||
| Q3 25 | 23.7% | — | ||
| Q2 25 | 35.1% | — | ||
| Q1 25 | 33.7% | — | ||
| Q4 24 | 25.4% | — | ||
| Q3 24 | 32.2% | — | ||
| Q2 24 | 22.0% | — |
资本支出强度FFIVRPRX
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 0.8% | — |
现金转化率FFIVRPRX
| Q1 26 | 3.55× | — | ||
| Q4 25 | 0.88× | 3.86× | ||
| Q3 25 | 1.09× | 2.44× | ||
| Q2 25 | 1.49× | 12.06× | ||
| Q1 25 | 1.76× | 2.50× | ||
| Q4 24 | 1.22× | 3.57× | ||
| Q3 24 | 1.49× | 1.29× | ||
| Q2 24 | 1.10× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FFIV
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
